{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:47:22Z","timestamp":1792158442140,"version":"4.4.0"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1097\/bor.0b013e328329a401","type":"journal-article","created":{"date-parts":[[2010,2,25]],"date-time":"2010-02-25T01:51:55Z","timestamp":1267062715000},"page":"244-250","source":"Crossref","is-referenced-by-count":22,"title":["Costimulation blockade in rheumatic diseases: where we are?"],"prefix":"10.1097","volume":"21","author":[{"given":"Vincent","family":"Go\u00ebb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya H","family":"Buch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward M","family":"Vital","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Emery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210128","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1084\/jem.20062259","article-title":"T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis","volume":"204","author":"Hirota","year":"2007","journal-title":"J Exp Med"},{"key":"R2-9-20210128","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1073\/pnas.86.4.1333","article-title":"CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines\/cytokines","volume":"86","author":"Thompson","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R3-9-20210128","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 control over Foxp3+ regulatory T cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"key":"R4-9-20210128","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1097\/01.tp.0000280545.14489.df","article-title":"Blockade of LIGHT\/HVEM and B7\/CD28 signaling facilitates long-term islet graft survival with development of allospecific tolerance","volume":"84","author":"Fan","year":"2007","journal-title":"Transplantation"},{"key":"R5-9-20210128","doi-asserted-by":"crossref","first-page":"5138","DOI":"10.1073\/pnas.91.11.5138","article-title":"Costimulator B7-1 confers antigen-presenting-cell function to parenchymal tissue and in conjunction with tumor necrosis factor alpha leads to autoimmunity in transgenic mice","volume":"91","author":"Guerder","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R6-9-20210128","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJM200103223441207","article-title":"Cytokine pathways and joint inflammation in rheumatoid arthritis","volume":"344","author":"Choy","year":"2001","journal-title":"N Engl J Med"},{"key":"R7-9-20210128","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1074-7613(01)00097-8","article-title":"CTLA-4 regulates induction of anergy in vivo","volume":"14","author":"Greenwald","year":"2001","journal-title":"Immunity"},{"key":"R8-9-20210128","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.4049\/jimmunol.181.3.1806","article-title":"CTLA4 expression is an indicator and regulator of steady-state CD4+ FoxP3+ T cell homeostasis","volume":"181","author":"Tang","year":"2008","journal-title":"J Immunol"},{"key":"R9-9-20210128","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1172\/JCI118220","article-title":"Transfer of rheumatoid arthritis into severe combined immunodeficient mice. The pathogenetic implications of T cell populations oligoclonally expanding in the rheumatoid joints","volume":"96","author":"Mima","year":"1995","journal-title":"J Clin Invest"},{"key":"R10-9-20210128","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/intimm\/dxn091","article-title":"Arthritis and pneumonitis produced by the same T cell clones from mice with spontaneous autoimmune arthritis","volume":"20","author":"Wakasa-Morimoto","year":"2008","journal-title":"Int Immunol"},{"key":"R11-9-20210128","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0092-8674(00)81989-3","article-title":"Organ-specific disease provoked by systemic autoimmunity","volume":"87","author":"Kouskoff","year":"1996","journal-title":"Cell"},{"key":"R12-9-20210128","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1002\/eji.1830261008","article-title":"Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2","volume":"26","author":"Webb","year":"1996","journal-title":"Eur J Immunol"},{"key":"R13-9-20210128","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1182\/blood-2002-03-0671","article-title":"Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis","volume":"100","author":"Ponchel","year":"2002","journal-title":"Blood"},{"key":"R14-9-20210128","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1006\/clim.2001.5003","article-title":"Cell surface CD28 levels define four CD4+ T cell subsets: abnormal expression in rheumatoid arthritis","volume":"99","author":"Salazar-Fontana","year":"2001","journal-title":"Clin Immunol"},{"key":"R15-9-20210128","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1126\/science.1496399","article-title":"Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule","volume":"257","author":"Linsley","year":"1992","journal-title":"Science"},{"key":"R16-9-20210128","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/35105024","article-title":"T-cell regulation by CD28 and CTLA-4","volume":"1","author":"Alegre","year":"2001","journal-title":"Nat Rev Immunol"},{"key":"R17-9-20210128","first-page":"2294","article-title":"The in vivo mechanism of action of CTLA4Ig","volume":"156","author":"Judge","year":"1996","journal-title":"J Immunol"},{"key":"R18-9-20210128","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1172\/JCI200318317","article-title":"CD28 costimulation independence of target organ versus circulating memory antigen-specific CD4+ T cells","volume":"112","author":"Fontenot","year":"2003","journal-title":"J Clin Invest"},{"key":"R19-9-20210128","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.clim.2007.08.019","article-title":"Abatacept modulates human dendritic cell-stimulated T-cell proliferation and effector function independent of IDO induction","volume":"126","author":"Davis","year":"2008","journal-title":"Clin Immunol"},{"key":"R20-9-20210128","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1136\/ard.2007.080713","article-title":"CTLA-4 directly inhibits osteoclast formation","volume":"67","author":"Axmann","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R21-9-20210128","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/art.10294","article-title":"Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion","volume":"46","author":"Moreland","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R22-9-20210128","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1056\/NEJMoa035075","article-title":"Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig","volume":"349","author":"Kremer","year":"2003","journal-title":"N Engl J Med"},{"key":"R23-9-20210128","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/art.21201","article-title":"Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial","volume":"52","author":"Kremer","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R24-9-20210128","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/art.22070","article-title":"Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study","volume":"54","author":"Weinblatt","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R25-9-20210128","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/ard.2007.080002","article-title":"Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multicentre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"67","author":"Schiff","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R26-9-20210128","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition","volume":"353","author":"Genovese","year":"2005","journal-title":"N Engl J Med"},{"key":"R27-9-20210128","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/ard.2006.055111","article-title":"Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial","volume":"66","author":"Weinblatt","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R28-9-20210128","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"R29-9-20210128","first-page":"579","article-title":"Development of a disease activity score based on judgment in clinical practice by rheumatologists","volume":"20","author":"van der Heijde","year":"1993","journal-title":"J Rheumatol"},{"key":"R30-9-20210128","doi-asserted-by":"crossref","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","article-title":"Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial","volume":"144","author":"Kremer","year":"2006","journal-title":"Ann Intern Med"},{"key":"R31-9-20210128","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/art.23397","article-title":"Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate","volume":"58","author":"Kremer","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R32-9-20210128","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/ard.2007.074773","article-title":"Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to antitumour necrosis factor therapy","volume":"67","author":"Genovese","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R34-9-20210128","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1136\/ard.2007.085084","article-title":"Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial","volume":"67","author":"Genant","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R35-9-20210128","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/1529-0131(199809)41:9<1583::AID-ART8>3.0.CO;2-H","article-title":"Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs","volume":"41","author":"Genant","year":"1998","journal-title":"Arthritis Rheum"},{"key":"R36-9-20210128","first-page":"S46","article-title":"Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis","volume":"25","author":"Sibilia","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"R37-9-20210128","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s10067-008-0979-9","article-title":"Abatacept and serious respiratory infections in patients with previous lung disease","volume":"27","author":"Miller","year":"2008","journal-title":"Clin Rheumatol"},{"key":"R38-9-20210128","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2007.083188","article-title":"Risk of serious infections during rituximab, abatacept and anakinra therapies for rheumatoid arthritis: meta-analyses of randomized placebo-controlled trials","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R39-9-20210128","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1093\/rheumatology\/keh586","article-title":"Leflunomide-induced subacute cutaneous lupus erythematosus","volume":"44","author":"Go\u00ebb","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"R40-9-20210128","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.semarthrit.2007.08.003","article-title":"Drug-induced lupus due to antitumor necrosis factor alpha agents","volume":"37","author":"Costa","year":"2008","journal-title":"Semin Arthritis Rheum"},{"key":"R41-9-20210128","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1002\/art.22811","article-title":"Development of psoriasis after B cell depletion with rituximab","volume":"56","author":"Dass","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R42-9-20210128","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/molehr\/5.1.84","article-title":"The CTLA-4 gene is expressed in placental fibroblasts","volume":"5","author":"Kaufman","year":"1999","journal-title":"Mol Hum Reprod"},{"key":"R43-9-20210128","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jri.2004.08.009","article-title":"Blockade of CD80 and CD86 at the time of implantation inhibits maternal rejection to the allogeneic fetus in abortion-prone matings","volume":"65","author":"Jin","year":"2005","journal-title":"J Reprod Immunol"},{"key":"R44-9-20210128","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","article-title":"Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial","volume":"372","author":"Ruperto","year":"2008","journal-title":"Lancet"},{"key":"R45-9-20210128","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/art.20945","article-title":"Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease","volume":"52","author":"Ravelli","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R46-9-20210128","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/bjo.2006.103721","article-title":"Adalimumab in the therapy of uveitis in childhood","volume":"91","author":"Biester","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R47-9-20210128","first-page":"1897","article-title":"Abatacept for refractory juvenile idiopathic arthritis-associated uveitis- a case report","volume":"35","author":"Angeles-Han","year":"2008","journal-title":"J Rheumatol"},{"issue":"Suppl II","key":"R48-9-20210128","first-page":"89","article-title":"Efficacy of abatacept in delaying the development of rheumatoid arthritis (RA) in adult patients with undifferentiated inflammatory arthritis at high risk of developing RA [Abstract]","volume":"67","author":"Emery","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R49-9-20210128","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1600-6143.2005.00749.x","article-title":"Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties","volume":"5","author":"Larsen","year":"2005","journal-title":"Am J Transplant"},{"key":"R50-9-20210128","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1191\/0961203305lu2136oa","article-title":"Block and tackle: CTLA4Ig takes on lupus","volume":"14","author":"Davidson","year":"2005","journal-title":"Lupus"},{"issue":"Program book supplement","key":"R51-9-20210128","first-page":"59","article-title":"The efficacy and safety of abatacept in SLE: results of a 12-months exploratory study [Abstract]","volume":"58","author":"Merrill","year":"2008","journal-title":"Arthritis Rheum"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0b013e328329a401","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:11:03Z","timestamp":1786039863000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002281-200905000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0b013e328329a401","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}